Taxotere + Cisplatin in Nasopharyngeal Carcinoma

Sanofi61 enrolled

Overview

Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin. Secondary objective: To assess tumor control and survival

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Neoplasms

Interventions

DocetaxelDRUG

75 mg/m²

CisplatinDRUG

75 mg/m²

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * International Union against Cancer stages III and IV newly diagnosed NPC Exclusion Criteria: * Inadequate bone marrow reserve * Inadequate renal function * Other primary malignancy * Evidence of distant metastases The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Hong Kong, Hong Kong

Outcomes

Primary Outcomes

Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.

Time frame: From administration of drug to end of study

Secondary Outcomes

Adverse Events

Time frame: From administration of drug to end of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.